Clinical Trial Results:
Paramedic Analgesia Comparing Ketamine and MorphiNe in trauma
Summary
|
|
EudraCT number |
2020-000154-10 |
Trial protocol |
GB |
Global end of trial date |
14 Feb 2025
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
02 Mar 2025
|
First version publication date |
02 Mar 2025
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
SOC.12/19-20
|
||
Additional study identifiers
|
|||
ISRCTN number |
ISRCTN14124474 | ||
US NCT number |
- | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
University of Warwick
|
||
Sponsor organisation address |
Gibbett Hill Road, Coventry, United Kingdom, CV4 7AL
|
||
Public contact |
Trial Manager, University of Warwick Clinical Trials Unit, 0247 6150478, packman@warwick.ac.uk
|
||
Scientific contact |
Dr Michael Smyth, University of Warwick Clinical Trials Unit, 0247 6150478, packman@warwick.ac.uk
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
14 May 2024
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
16 Nov 2023
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
14 Feb 2025
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
The primary objective of this trial is to determine whether paramedic administered ketamine or morphine provides more effective pain relief for patients reporting severe pain following trauma. This will be measured by using a 0-10 numeric rating scale and the Sum of Pain Intensity Difference (SPID).
|
||
Protection of trial subjects |
Procedures for emergency unblinding.
procedures in place to treat any distressing side effects e.g. abnormal behavioural reactions.
Options for rescue analgesia in the event trial analgesia was ineffective.
procedures in place for cases of accidental overdose
procedures in place for addressing non-disclosed pregnancy
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
20 Oct 2021
|
||
Long term follow-up planned |
Yes
|
||
Long term follow-up rationale |
Safety, Efficacy | ||
Long term follow-up duration |
6 Months | ||
Independent data monitoring committee (IDMC) involvement? |
Yes
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
United Kingdom: 449
|
||
Worldwide total number of subjects |
449
|
||
EEA total number of subjects |
0
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
1
|
||
Adults (18-64 years) |
202
|
||
From 65 to 84 years |
155
|
||
85 years and over |
91
|
|
||||||||||
Recruitment
|
||||||||||
Recruitment details |
- | |||||||||
Pre-assignment
|
||||||||||
Screening details |
Patients were eligible for inclusion if they had suffered an acute traumatic injury, were at least 16 years of age or over, reported a pain score of 7 or greater on a 0-10 numeric rating score (NRS) and, in the opinion of the attending paramedic, would normally require parenteral morphine for analgesia. | |||||||||
Period 1
|
||||||||||
Period 1 title |
overall trial (overall period)
|
|||||||||
Is this the baseline period? |
Yes | |||||||||
Allocation method |
Randomised - controlled
|
|||||||||
Blinding used |
Double blind | |||||||||
Roles blinded |
Subject, Investigator | |||||||||
Blinding implementation details |
Treatment packs were manufactured and supplied by an appropriately licenced pharmaceutical company. Treatment packs, containing either ketamine or morphine, were identical in appearance, apart from their unique sequential number. Packs were distributed by the trial drug manufacturer to ensure equal proportions across participating sites. Individual participant randomisation occurred when the attending paramedic opened the trial treatment pack.
|
|||||||||
Arms
|
||||||||||
Are arms mutually exclusive |
Yes
|
|||||||||
Arm title
|
morphine | |||||||||
Arm description |
- | |||||||||
Arm type |
Active comparator | |||||||||
Investigational medicinal product name |
morphine sulphate
|
|||||||||
Investigational medicinal product code |
||||||||||
Other name |
||||||||||
Pharmaceutical forms |
Solution for injection
|
|||||||||
Routes of administration |
Intraosseous use, Intravenous use
|
|||||||||
Dosage and administration details |
titrate to effect. maximum cummulative dose 20mg
|
|||||||||
Investigational medicinal product name |
ketamine hydrochloride
|
|||||||||
Investigational medicinal product code |
||||||||||
Other name |
||||||||||
Pharmaceutical forms |
Solution for injection
|
|||||||||
Routes of administration |
Intraosseous use, Intravenous use
|
|||||||||
Dosage and administration details |
titrate to effect. maximum cummulative dose 30mg
|
|||||||||
Arm title
|
ketamine | |||||||||
Arm description |
- | |||||||||
Arm type |
Experimental | |||||||||
Investigational medicinal product name |
ketamine
|
|||||||||
Investigational medicinal product code |
||||||||||
Other name |
||||||||||
Pharmaceutical forms |
Solution for injection
|
|||||||||
Routes of administration |
Intraosseous use, Intravenous use
|
|||||||||
Dosage and administration details |
Titrate to effect. Maximum cummulative dose 30mg.
|
|||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
morphine
|
||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
ketamine
|
||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
morphine
|
||
Reporting group description |
- | ||
Reporting group title |
ketamine
|
||
Reporting group description |
- |
|
|||||||||||||
End point title |
SPID score | ||||||||||||
End point description |
|||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
time from first drug administration to arrival at hospital
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Adjusted estimate | ||||||||||||
Comparison groups |
morphine v ketamine
|
||||||||||||
Number of subjects included in analysis |
449
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
= 0.7 | ||||||||||||
Method |
Regression, Linear | ||||||||||||
Parameter type |
Mean difference (final values) | ||||||||||||
Point estimate |
0.1
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
-0.43 | ||||||||||||
upper limit |
0.64 |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
from administration of drug to 6 months post administration
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
CTCAE | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
5
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
morphine
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
ketamine
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 0.5% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||||||
Substantial protocol amendments (globally) |
|||||||
Were there any global substantial amendments to the protocol? Yes | |||||||
Date |
Amendment |
||||||
22 Dec 2020 |
Update to investigational medicinal product description to permit intraosseous administration
|
||||||
14 Apr 2021 |
Update to include risk assessment for concomitant use of a COVID-19 vaccine |
||||||
23 Jun 2021 |
Revision to consent process. New and revised letters and consent forms |
||||||
30 Jun 2021 |
Protocol amendment to correct dosing table. Minor update to eConsent forms
|
||||||
25 Oct 2021 |
Change of PI at Yorkshire site
|
||||||
05 May 2022 |
Update exclusion criteria and participant information sheet PIS |
||||||
04 Oct 2022 |
Extension of trial recruitment whilst pending official extension.
|
||||||
15 Dec 2022 |
Extension of PACKMaN trial.
|
||||||
04 Oct 2023 |
Protocol amendment to update unblinding process and results letter for participants. Addition of final results letter for patients.
|
||||||
25 Oct 2023 |
Addition of participant unblinding letter
|
||||||
17 Nov 2023 |
Protocol amendment to update names of TSC PPI members
|
||||||
25 Jan 2024 |
Protocol amendment to provide clarity on who the hospital data collection form will be collected from and data retention where only verbal assent is in place. |
||||||
Interruptions (globally) |
|||||||
Were there any global interruptions to the trial? Yes | |||||||
|
|||||||
Limitations and caveats |
|||||||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||||||
None reported |